Drug Database · Clinicians

Polymyxin b

Brands (8) Colymyx, Mixcen, MyxiGet…Show all

Antibacterial (polymyxin) PH FDA category

Rx · Prescription drug9 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6, version date June 22, 2026 (Polymyxin B · Xellia Pharmaceuticals USA LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa.

It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae, specifically meningeal infections. Escherichia coli, specifically urinary tract infections. Aerobacter aerogenes, specifically bacteremia.

Klebsiella pneumoniae, specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

CONTRAINDICATIONS This drug is contraindicated in persons with a prior history of hypersensitivity reactions to polymyxins.

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION PARENTERAL Intravenous Dissolve 500,000 polymyxin B units in 300 to 500 mL solutions for parenteral 5% Dextrose Injection for continuous drip. Adults and children 15,000 to 25,000 units/kg body weight/day in individuals with normal kidney function. This amount should be reduced from 15,000 units/kg downward for individuals with kidney impairment.

Infusions may be given every 12 hours; however, the total daily dose must not exceed 25,000 units/kg/day. Infants Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects. Intramuscular Not recommended routinely because of severe pain at injection sites, particularly in infants and children.

Dissolve 500,000 Polymyxin B units in 2 mL Sterile Water for Injection or 0.9 % Sodium Chloride Injection or Procaine Hydrochloride Injection 1%. Adults and children 25,000 to 30,000 units/kg/day. This should be reduced in the presence of renal impairment. The dosage may be divided and given at either 4 or 6 hour intervals.

Infants Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects. Note: Doses as high as 45,000 units/kg/day have been used in limited clinical studies in treating prematures and newborn infants for sepsis caused by Ps aeruginosa. Intrathecal A treatment of choice for Ps aeruginosa meningitis.

Dissolve 500,000 polymyxin B units in 10 mL 0.9 % Sodium Chloride Injection USP for 50,000 units per mL dosage unit. Adults and children over 2 years of age Dosage is 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.

Children under 2 years of age 20,000 units once daily, intrathecally for 3 to 4 days or 25,000 units once every other day. Continue with a dose of 25,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal. IN THE INTEREST OF SAFETY, SOLUTIONS OF PARENTERAL USE SHOULD BE STORED UNDER REFRIGERATION, AND ANY UNUSED PORTIONS SHOULD BE DISCARDED AFTER 72 HOURS.

TOPICAL Ophthalmic Dissolve 500,000 polymyxin B units in 20 to 50 mL sterile water for injection or 0.9% sodium chloride injection, USP for a 10,000 to 25,000 units per mL concentration. For the treatment of Ps aeruginosa infections of the eye, a concentration of 0.1 percent to 0.25 percent (10,000 units to 25,000 units per mL) is administered 1 to 3 drops every hour, increasing the intervals as response indicates.

Subconjunctival injection of up to 100,000 units/day may be used for the treatment of Ps aeruginosa infections of the cornea and conjunctiva. Note: Avoid total systemic and ophthalmic instillation over 25,000 units/kg/day.

Dosing: Altered kidney function

From the US FDA label · Dosage and administration (renal excerpts)

Adults and children 15,000 to 25,000 units/kg body weight/day in individuals with normal kidney function.

This amount should be reduced from 15,000 units/kg downward for individuals with kidney impairment.

Infants Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.

This should be reduced in the presence of renal impairment.

Infants Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Lyophilized powder for injection: 500,000 units
  • Powder for solution for injection: 500,000 units
  • Lyophilized powder for solution for inejction: 500,000 IU
  • Lyophilized powder for solution for injection: 500,000 Units
  • Lyophilized powder for solution for intrathecal injection: 500,000 Units

Registered products in the Philippines

9 products registered with the Food and Drug Administration (FDA) Philippines list Polymyxin b as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products9
Philippine FDA-registered products for Polymyxin b
Package insert
ColymyxPolymyxin B (as sulfate)
500,000 Units Powder for Solution for Injection (Intrathecal /IM/IV)USP Type I amber glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal x 5 mL (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Philcare Pharma Inc.Importer: One Dexcel Pharma Inc.
DRP-14162-01
Jul 6, 2028
MixcenPolymyxin B
500,000 Units Lyophilized Powder for Injection (Intrathecal/IM/IV)USP Type I Amber Glass Vial x 10 mL with Grey Butyl Rubber Stopper, Aluminum Seal and Blue PP flip-off cap (Box of 1's)
Rx
Venus Remedies Ltd.India
Central West Medicale Inc.Importer: 2MG Incorporated
DRP-17416-01
Dec 12, 2030
MyxiGetPolymyxin B
500,000 units Lyophilized Powder for Injection (Intrathecal/IM/IV)USP Type I amber glass vial x 10 mL with grey butyl rubber stopper, aluminum seal and blue PP flip-off cap (Box of 1's)
Rx
Venus Remedies Ltd.India
2MG Incorporated
DRP-17416
Dec 12, 2030
NonePolymyxin B (as Sulfate)
500,000 Units Lyophilized Powder for Injection (Intrathecal/I.M./I.V.)USP Type I amber glass vial with 20 mm slotted grey bromobutyl rubber stopper and 20 mm aluminum flip off seal royal blue color (Box of 1's)
Rx
Gufic Biosciences LimitedIndia
Medethix, Inc. .
DRP-18820
Sep 14, 2031
PolimyroPolymyxin B (as Sulfate)
500,000 Units Lyophilized Powder for Solution for Injection (Intrathecal/IM/IV)5 mL & 10 mL Type I Tubular Amber Glass Vial with bromobutyl rubber stopper aluminum seal and white flip-off cap - (Box of 1's)
Rx
Indasi Lifescience Pvt. Ltd.India
Aglobal Care, Inc.
DRR-17981
May 4, 2031
Poly-MxBPolymyxin B Sulfate
500,000 Units Lyophilized Powder for Solution for Intrathecal Injection (I.M./I.V.)In 5mL USP Type I Amber Colored Glass Vial Box of 1’s
Rx
Bharat Serums and Vaccines LimitedPhilippines
BSV Bioscience Phils., Inc.
DR-XY45801
Mar 3, 2032
Polyject-BPolymyxin B (as sulfate)
500,000 Units Powder for Solution for Injection (Intrathecal/IM/IV)USP Type I Amber Glass vial with Grey Bromobutyl rubber Stopper and Aluminum Flip-off Seal x 5mL (Box of 1's)
Rx
Swiss Parenterals LtdIndia
One Dexcel Pharma Inc.
DRP-14162
Jul 6, 2028
PolyxinPolymyxin B (as sulfate)
500,000 units Powder for Solution for Injection (Intrathecal/IM/IV)Type I amber glass vial x 5 mL-capacity with grey bromobutyl rubber stopper, aluminum seal and royal blue flip-off cap (Box of 1's)
Rx
Guific Biosciences LimitedIndia
International Apex Pharmaceutical, Inc.
DR-XY49537
Oct 7, 2030
PymyxonPolymyxin B (as sulfate)
500,000 IU Lyophilized Powder For Solution For Inejction (IV/IM/IA)10 mL capacity USP Type I clear glass vial with rubber stopper and grey flip-off seal (Box of 10’s)
Rx
Gland Pharma LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-18059
Apr 30, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

WARNINGS Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Polymyxin B for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

Electrolyte and Acid/Base Abnormalities Postmarketing cases of renal tubulopathy (i.e., Pseudo-Bartter syndrome) have been identified with the use of intravenous polymyxins, including polymyxin B (see ADVERSE REACTIONS). All cases reported hypokalemia and metabolic alkalosis. Other common findings included hypocalcemia, hypomagnesemia, increased potassium in the urine, normal serum creatinine, and normal blood pressure.

Consider electrolyte monitoring during treatment. Normalization of electrolyte abnormalities may require drug discontinuation.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS See WARNING box. Nephrotoxic reactions Albuminuria, cylinduria, azotemia, and rising blood levels without any increase in dosage. Renal system reactions electrolyte and acid/base abnormalities (i.e.,Pseudo-Bartter syndrome) Neurotoxic reactions Facial flushing, dizziness progressing to ataxia, drowsiness, peripheral paresthesias (circumoral and stocking glove), apnea due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdosage, and signs of meningeal irritation with intrathecal administration, e.g., fever, headache, stiff neck and increased cell count and protein cerebrospinal fluid.

Other reactions occasionally reported Drug fever, urticarial rash, pain (severe) at intramuscular injection sites, and thrombophlebitis at intravenous injection sites. To report SUSPECTED ADVERSE REACTIONS, contact Xellia Pharmaceuticals Inc at [email protected] or 1-833-295-6953, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The drug is excreted slowly by the kidneys.

Pharmacokinetics (US label) US FDA label

CLINICAL PHARMACOLOGY Polymyxin B sulfate has a bactericidal action against almost all gram-negative bacilli except the Proteus group. Polymyxins increase the permeability of bacterial cell membrane leading to death of the cell. All gram positive bacteria, fungi, and gram-negative cocci are resistant to polymyxin B. For specific information regarding susceptibility test criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: www.fda.gov/STIC.

Polymyxin B sulfate is not absorbed from the normal alimentary tract. Since the drug loses 50 percent of its activity in the presence of serum, active blood levels are low. Repeated injections may give a cumulative effect. Levels tend to be higher in infants and children. The drug is excreted slowly by the kidneys. Tissue diffusion is poor and the drug does not pass the blood brain barrier into the cerebrospinal fluid.

In therapeutic dosage, polymyxin B sulfate causes some nephrotoxicity with tubule damage to a slight degree.

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Polymyxin B (as sulfate)
PNF listingInj.: 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vialRestrictions: Reserve antimicrobial (PNF)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Polymyxin B · Xellia Pharmaceuticals USA LLC [US FDA-approved label, version 13, June 22, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .